Spotlight On... AMRI's revenues soar 45% as refocus on contract manufacturing pays off; Packagers create alliance; state-owned company in South Africa to make antiretrovirals; and more...

AMRI ($AMRI), having refocused on its contract manufacturing operations, saw the changes pay off last year, according to its recently released earnings. The Albany, NY-based CDMO reported that revenue grew 45% in 2015, to $402.3 million, up from $276.6 million from the previous year. The contractor has moved from its heavy reliance on drug discovery, to more emphasis on production, adding plants and capabilities through a series of deals in the last two years. More from FierceCRO

> Eight pharmaceutical packaging companies have formed the Matrix Alliance, through which they intend, among other aims, to test new presterilized container and nested closure systems for injectable medicines and ensure the compatibility of components from different members. Release

> The FDA will hold a workshop to get ideas about a proposed pilot program required under the Drug Supply Chain Security Act (DSCSA). Notice

> Quay Pharma says it has gotten MHRA approval to manufacture commercial batches of drugs at its two production sites in Deeside, North Wales, and Bromborough, near Liverpool. Report

> Ketlaphela, a state-run pharmaceutical company formed a year ago in South Africa, says it will begin manufacturing antiretroviral drugs in 2019. Report

Suggested Articles

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

The $520 million investment includes $230 million for AZ's Dunkirk, France manufacturing site dedicated to inhalers and $275 million for R&D.

Manufacturing issues have caused GlaxoSmithKline to halt production and distribution of Excedrin, which has led to outages at some pharmacies.